IPSEY लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 23:41):

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases...

Stats
आज की मात्रा	479.00
औसत मात्रा	1 524.00
बाजार मूल्य	9.94B
Last Dividend	$0.324 ( 2023-06-02 )
Next Dividend	$0 ( N/A )
P/E	14.96
ATR14	$0 (0.00%)

Ipsen S.A. सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध

10 सबसे अधिक नकारात्मक सहसंबंध

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Ipsen S.A. वित्तीय

Annual	2023
राजस्व:	$3.13B
सकल लाभ:	$2.35B (75.10 %)
EPS:	$7.79

FY	2023
राजस्व:	$3.13B
सकल लाभ:	$2.35B (75.10 %)
EPS:	$7.79

FY	2022
राजस्व:	$3.16B
सकल लाभ:	$2.63B (83.28 %)
EPS:	$1.970

FY	2021
राजस्व:	$3.00B
सकल लाभ:	$2.46B (82.06 %)
EPS:	$1.948

Financial Reports:

No articles found.

Ipsen S.A. Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0.324 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Ipsen S.A. Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 6.15 - Stable (22.93%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.262	2013-06-11
Last Dividend	$0.324	2023-06-02
Next Dividend	$0	N/A
Payout Date	2023-06-27
Next Payout Date	N/A
# dividends	11	--
Total Paid Out	$3.05	--
Avg. Dividend % Per Year	0.00%	--
Score	3.56	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	6.15
Div. Directional Score	9.82	--

Next Divdend (Est)
(2025-03-31)

$0.339 Estimate 3.11 %

Dividend Stability

0.25 Very Poor

Dividend Score

3.56

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for OTC

Symbol	Title	Last dividend	Frequency	Yearly Dividend
SKHHY	Ex Dividend Knight	2023-09-05	Semi-Annually	0.00%
GTPS	Ex Dividend Knight	2023-09-14	Quarterly	0.00%
ALIZY	Ex Dividend Junior	2023-05-05	Annually	0.00%
NCBDF	Ex Dividend Junior	2023-09-28	Annually	0.00%
CRHKY	Ex Dividend Knight	2023-08-29	Semi-Annually	0.00%
TBLMY	Ex Dividend Junior	2023-07-06	Annually	0.00%
HRST	Ex Dividend Junior	2023-06-22	Semi-Annually	0.00%
AXAHY	Ex Dividend Junior	2023-05-04	Annually	0.00%
PCLB	Ex Dividend Knight	2023-09-01	Quarterly	0.00%
DWNX	Ex Dividend Knight	2023-09-28	Quarterly	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.206	1.500	5.88	8.82	[0 - 0.5]
returnOnAssetsTTM	0.102	1.200	6.60	7.92	[0 - 0.3]
returnOnEquityTTM	0.178	1.500	9.13	10.00	[0.1 - 1]
payoutRatioTTM	0.155	-1.000	8.45	-8.45	[0 - 1]
currentRatioTTM	1.167	0.800	9.17	7.33	[1 - 3]
quickRatioTTM	0.864	0.800	9.63	7.70	[0.8 - 2.5]
cashRatioTTM	0.325	1.500	9.31	10.00	[0.2 - 2]
debtRatioTTM	0.0626	-1.500	8.96	-10.00	[0 - 0.6]
interestCoverageTTM	37.44	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	10.20	2.00	6.60	10.00	[0 - 30]
freeCashFlowPerShareTTM	7.99	2.00	6.00	10.00	[0 - 20]
debtEquityRatioTTM	0.103	-1.500	9.59	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.817	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	0.314	1.000	5.73	5.73	[0.1 - 0.6]
cashFlowToDebtRatioTTM	2.13	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.495	0.800	-0.0358	-0.0286	[0.5 - 2]
Total Score				13.49

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	3.63	1.000	9.73	0	[1 - 100]
returnOnEquityTTM	0.178	2.50	9.44	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	7.99	2.00	7.34	10.00	[0 - 30]
dividendYielPercentageTTM	1.145	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	10.20	2.00	6.60	10.00	[0 - 30]
payoutRatioTTM	0.155	1.500	8.45	-8.45	[0 - 1]
pegRatioTTM	0.0973	1.500	-2.68	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.270	1.000	5.76	0	[0.1 - 0.5]
Total Score				6.15

Ipsen S.A.

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, chronic renal failure, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. The company also offers Smecta for chronic and acute diarrhea, and pain associated with functional bowel diseases; Forlax for constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. In addition, it provides Xermelo for the carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Protect, a food supplement; SmectaGas, a medical device used in the symptomatic treatment of gas-related gastrointestinal disorders and relief of gas-related symptoms; and Etiasa for inflammatory bowel diseases. Further, the company offers other consumer healthcare products in the gastro-intestinal area, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Braintree Laboratories; Ethypharm; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.